MY205197A - Methyllactam ring compound and pharmaceutical use thereof - Google Patents
Methyllactam ring compound and pharmaceutical use thereofInfo
- Publication number
- MY205197A MY205197A MYPI2020003891A MYPI2020003891A MY205197A MY 205197 A MY205197 A MY 205197A MY PI2020003891 A MYPI2020003891 A MY PI2020003891A MY PI2020003891 A MYPI2020003891 A MY PI2020003891A MY 205197 A MY205197 A MY 205197A
- Authority
- MY
- Malaysia
- Prior art keywords
- methyllactam
- pharmaceutical use
- ring compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018036307 | 2018-03-01 | ||
| PCT/JP2019/007799 WO2019168096A1 (ja) | 2018-03-01 | 2019-02-28 | メチルラクタム環化合物及びその医薬用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY205197A true MY205197A (en) | 2024-10-07 |
Family
ID=67806229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2020003891A MY205197A (en) | 2018-03-01 | 2019-02-28 | Methyllactam ring compound and pharmaceutical use thereof |
Country Status (21)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI805699B (zh) * | 2018-03-01 | 2023-06-21 | 日商日本煙草產業股份有限公司 | 甲基內醯胺環化合物及其用途 |
| TWI805727B (zh) | 2018-04-04 | 2023-06-21 | 日商日本煙草產業股份有限公司 | 經雜芳基取代之吡唑化合物及其醫藥用途 |
| CN114585387B (zh) * | 2019-09-04 | 2024-10-29 | 日本烟草产业株式会社 | 利用联用药物的糖尿病的治疗或预防方法 |
| CN114641314B (zh) * | 2019-09-04 | 2024-05-28 | 日本烟草产业株式会社 | 慢性肾脏病的治疗或预防方法 |
| EP4122495A4 (en) * | 2020-03-19 | 2024-03-27 | Japan Tobacco Inc. | Treatment or prevention method for chronic heart failure |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3657282A (en) * | 1969-01-23 | 1972-04-18 | Merck & Co Inc | Carboxyepoxyethyl-1-phosphonic acid and derivatives |
| FR2665898B1 (fr) | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| JPH04247081A (ja) | 1991-02-01 | 1992-09-03 | Takeda Chem Ind Ltd | 5員複素環酸アミド類 |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| RU2332412C2 (ru) | 2003-02-07 | 2008-08-27 | Дайити Фармасьютикал Ко., Лтд. | Производные пиразола |
| AU2004200420A1 (en) | 2003-03-11 | 2004-09-30 | Astellas Pharma Inc. | Inhibitor of cyclooxygenase |
| JP2006182648A (ja) | 2003-04-08 | 2006-07-13 | Dai Ichi Seiyaku Co Ltd | 7員複素環誘導体 |
| US20050075375A1 (en) | 2003-05-14 | 2005-04-07 | Anadys Pharmaceuticals, Inc. | Heterocyclic compounds for treating hepatitis C virus |
| TW200526588A (en) | 2003-11-17 | 2005-08-16 | Smithkline Beecham Corp | Chemical compounds |
| TW200526641A (en) | 2003-12-26 | 2005-08-16 | Daiichi Seiyaku Co | Amidopyrazole derivatives |
| DE602005017895D1 (de) | 2004-07-07 | 2010-01-07 | Merck & Co Inc | Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren |
| US9168278B2 (en) | 2004-11-16 | 2015-10-27 | Gw Pharma Limited | Use for cannabinoid |
| JP2008007405A (ja) | 2004-12-07 | 2008-01-17 | Takeda Chem Ind Ltd | カルボキサミド誘導体 |
| JP4137956B2 (ja) * | 2005-06-08 | 2008-08-20 | 日本たばこ産業株式会社 | 複素環化合物 |
| KR100970294B1 (ko) | 2005-06-08 | 2010-07-15 | 니뽄 다바코 산교 가부시키가이샤 | 복소환 화합물 |
| CN101243074A (zh) * | 2005-06-08 | 2008-08-13 | 日本烟草产业株式会社 | 杂环化合物 |
| WO2007034279A2 (en) | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | C3a antagonists and pharmaceutical compositions thereof |
| EP1991528A2 (en) | 2006-01-18 | 2008-11-19 | Siena Biotech S.p.A. | Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof |
| CA2650566A1 (en) * | 2006-04-27 | 2007-11-08 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators |
| US20080027014A1 (en) | 2006-07-28 | 2008-01-31 | Tanabe Seiyaku Co., Ltd. | Novel SGLT inhibitors |
| SG173409A1 (en) | 2006-11-24 | 2011-08-29 | Ac Immune Sa | N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers |
| EP2121619A2 (en) | 2006-11-24 | 2009-11-25 | AC Immune S.A. | Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
| TW200901974A (en) | 2007-01-16 | 2009-01-16 | Wyeth Corp | Compounds, compositions, and methods of making and using them |
| EP2064222B1 (en) * | 2007-04-02 | 2014-05-07 | Theracos, Inc. | Benzylic glycoside derivatives and methods of use |
| WO2009091813A1 (en) | 2008-01-14 | 2009-07-23 | Wyeth | Compounds useful as alpha7 nicotinic acetylcholine receptor agonists |
| EP2349484A2 (en) | 2008-07-15 | 2011-08-03 | Novartis AG | Heteroaryl derivatives as dgat1 inhibitors |
| SG10201502484SA (en) | 2010-03-30 | 2015-05-28 | Verseon Corp | Multisubstituted aromatic compounds as inhibitors of thrombin |
| AR087701A1 (es) | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
| JP6929792B2 (ja) * | 2015-02-16 | 2021-09-01 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| BR112018016671A2 (pt) * | 2016-02-16 | 2018-12-26 | The University Of Queensland | sulfonilureias e compostos relacionados e uso do mesmo |
| TWI805699B (zh) * | 2018-03-01 | 2023-06-21 | 日商日本煙草產業股份有限公司 | 甲基內醯胺環化合物及其用途 |
| TWI805727B (zh) | 2018-04-04 | 2023-06-21 | 日商日本煙草產業股份有限公司 | 經雜芳基取代之吡唑化合物及其醫藥用途 |
-
2019
- 2019-02-27 TW TW108106807A patent/TWI805699B/zh active
- 2019-02-28 JP JP2019035140A patent/JP7206132B2/ja active Active
- 2019-02-28 AU AU2019227770A patent/AU2019227770B2/en active Active
- 2019-02-28 MY MYPI2020003891A patent/MY205197A/en unknown
- 2019-02-28 MA MA052427A patent/MA52427A/fr unknown
- 2019-02-28 CA CA3087859A patent/CA3087859A1/en active Pending
- 2019-02-28 IL IL276311A patent/IL276311B2/en unknown
- 2019-02-28 KR KR1020207025856A patent/KR102795351B1/ko active Active
- 2019-02-28 CN CN201980016238.4A patent/CN111757877B/zh active Active
- 2019-02-28 PE PE2020001287A patent/PE20210123A1/es unknown
- 2019-02-28 MX MX2020009070A patent/MX2020009070A/es unknown
- 2019-02-28 SG SG11202007120UA patent/SG11202007120UA/en unknown
- 2019-02-28 EP EP19760111.5A patent/EP3760624A4/en active Pending
- 2019-02-28 BR BR112020016788-6A patent/BR112020016788A2/pt active IP Right Grant
- 2019-02-28 AR ARP190100503A patent/AR114418A1/es active IP Right Grant
- 2019-02-28 US US16/289,500 patent/US11014910B2/en active Active
- 2019-02-28 WO PCT/JP2019/007799 patent/WO2019168096A1/ja not_active Ceased
-
2020
- 2020-07-24 ZA ZA2020/04600A patent/ZA202004600B/en unknown
- 2020-08-24 SA SA520420037A patent/SA520420037B1/ar unknown
- 2020-08-26 CL CL2020002199A patent/CL2020002199A1/es unknown
- 2020-08-27 PH PH12020551340A patent/PH12020551340A1/en unknown
-
2021
- 2021-04-16 US US17/233,273 patent/US20220064148A1/en not_active Abandoned
-
2023
- 2023-01-04 JP JP2023000037A patent/JP2023026566A/ja active Pending
- 2023-06-28 US US18/343,415 patent/US20240174646A1/en not_active Abandoned
-
2024
- 2024-12-09 JP JP2024214451A patent/JP2025026615A/ja active Pending
-
2025
- 2025-07-07 US US19/261,942 patent/US20260152490A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501685A1 (en) | Quinazone compound | |
| ZA202206923B (en) | New methylquinazolinone derivatives | |
| PH12016502103B1 (en) | Novel disubstituted 1,2, 4-triazine compound | |
| PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| PH12020551340A1 (en) | Methyllactam ring compound and pharmaceutical use thereof | |
| PH12019500849A1 (en) | Naphthyridinone derivatives and their use inthe treatment of arrhythmia | |
| MX2021007247A (es) | Derivados de rapamicina. | |
| CR20200151A (es) | Compuestos bicíclicos y métodos de utilización de los mismos | |
| PH12016502246A1 (en) | Carboxamide derivatives | |
| MX2018014813A (es) | Composiciones antibacterianas. | |
| MY194711A (en) | Novel annelated phenoxyacetamides | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| MX2016014946A (es) | Derivados de carboxamida. | |
| PH12020551341A1 (en) | 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof | |
| PH12020550763A1 (en) | Pyridinone derivatives and their use as selective alk-2 inhibitors | |
| MX379373B (es) | Derivado de sulfonamida heterocíclico y medicina que contiene el mismo. | |
| MY194941A (en) | C-glycoside derivatives having fused phenyl ring or pharmaceutically acceptable salts thereof, method for preparing the same and pharmaceutical composition comprising the same | |
| PH12020500233A1 (en) | Adamantylmethylamine derivative and use thereof as pharmaceutical | |
| JOP20230099A1 (ar) | تركيبات صيدلية | |
| BR112017025356A2 (pt) | composto, composição farmacêutica, e, fármaco. | |
| EA201891136A1 (ru) | Фармацевтическая композиция, содержащая в качестве активного ингредиента производное 7-азаиндолин-2-она или его фармацевтически приемлемую соль | |
| TR201722852A2 (tr) | Mesalazi̇ni̇n oral farmasöti̇k kompozi̇syonlari | |
| MX2018007272A (es) | Composicion farmaceutica de liberacion pulsatil que comprende naftazona o una de sus sales. | |
| PH12016502247A1 (en) | Carboxamide derivatives |